|
1
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colombo PE, Fabbro M, Theillet C, Bibeau
F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to
treatment in the primary management of epithelial ovarian cancer.
Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI
|
|
5
|
Wallace S, Kumar A, Mc Gree M, Weaver A,
Mariani A, Langstraat C, Dowdy S, Bakkum-Gamez J and Cliby W:
Efforts at maximal cytoreduction improve survival in ovarian cancer
patients, even when complete gross resection is not feasible.
Gynecol Oncol. 145:21–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li YC, Wang Y, Li DD, Zhang Y, Zhao TC and
Li CF: Procaine is a specific DNA methylation inhibitor with
anti-tumor effect for human gastric cancer. J Cell Biochem.
119:2440–2449. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parry L and Clarke AR: The roles of the
methyl-CpG binding proteins in cancer. Genes Cancer. 2:618–630.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Defossez PA and Stancheva I: Biological
functions of methyl-CpG-binding proteins. Prog Mol Biol Transl Sci.
101:377–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stirzaker C, Song JZ, Ng W, Du Q,
Armstrong NJ, Locke WJ, Statham AL, French H, Pidsley R,
Valdes-Mora F, et al: Methyl-CpG-binding protein MBD2 plays a key
role in maintenance and spread of DNA methylation at CpG islands
and shores in cancer. Oncogene. 36:1328–1338. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du Q, Luu PL, Stirzaker C and Clark SJ:
Methyl-CpG-binding domain proteins: Readers of the epigenome.
Epigenomics. 7:1051–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lai AY and Wade PA: Cancer biology and
NuRD: A multifaceted chromatin remodelling complex. Nat Rev Cancer.
11:588–596. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramirez J, Dege C, Kutateladze TG and
Hagman J: MBD2 and multiple domains of CHD4 are required for
transcriptional repression by Mi-2/NuRD complexes. Mol Cell Biol.
32:5078–5088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cai Y, Geutjes EJ, de Lint K, Roepman P,
Bruurs L, Yu LR, Wang W, van Blijswijk J, Mohammad H, de Rink I, et
al: The NuRD complex cooperates with DNMTs to maintain silencing of
key colorectal tumor suppressor genes. Oncogene. 33:2157–2168.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan CP and Nakielny S: Control of the DNA
methylation system component MBD2 by protein arginine methylation.
Mol Cell Biol. 26:7224–7235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita H, Fujii R, Aratani S, Amano T,
Fukamizu A and Nakajima T: Antithetic effects of MBD2a on gene
regulation. Mol Cell Biol. 23:2645–2657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu D, Hunter SB, Vertino PM and Van Meir
EG: Overexpression of MBD2 in glioblastoma maintains epigenetic
silencing and inhibits the antiangiogenic function of the tumor
suppressor gene BAI1. Cancer Res. 71:5859–5870. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan ZX, Zhang XY, Chen SR and Li CZ:
Upregulated exosomal miR-221/222 promotes cervical cancer via
repressing methyl-CpG-binding domain protein 2. Eur Rev Med
Pharmacol Sci. 23:3645–3653. 2019.PubMed/NCBI
|
|
18
|
Izquierdo-Torres E, Hernández-Oliveras A,
Meneses-Morales I, Rodríguez G, Fuentes-García G and
Zarain-Herzberg Á: Resveratrol up-regulates ATP2A3 gene expression
in breast cancer cell lines through epigenetic mechanisms. Int J
Biochem Cell Biol. 113:37–47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pontes TB, Chen ES, Gigek CO, Calcagno DQ,
Wisnieski F, Leal MF, Demachki S, Assumpção PP, Artigiani R,
Lourenço LG, et al: Reduced mRNA expression levels of MBD2 and MBD3
in gastric carcinogenesis. Tumour Biol. 35:3447–3453. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
May S, Owen H, Phesse TJ, Greenow KR,
Jones GR, Blackwood A, Cook PC, Towers C, Gallimore AM, Williams
GT, et al: Mbd2 enables tumourigenesis within the intestine while
preventing tumour-promoting inflammation. J Pathol. 245:270–282.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu W, Wang N, Lu M, Du XJ and Xing BC:
MBD2 as a novel marker associated with poor survival of patients
with hepatocellular carcinoma after hepatic resection. Mol Med Rep.
14:1617–1623. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mian OY, Wang SZ, Zhu SZ, Gnanapragasam
MN, Graham L, Bear HD and Ginder GD: Methyl-binding domain protein
2-dependent proliferation and survival of breast cancer cells. Mol
Cancer Res. 9:1152–1162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang
C and Wu M: Decreased levels of miR-224 and the passenger strand of
miR-221 increase MBD2, suppressing maspin and promoting colorectal
tumor growth and metastasis in mice. Gastroenterology. 145:853–864
e9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thul PJ and Lindskog C: The human protein
atlas: A spatial map of the human proteome. Protein Sci.
27:233–244. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thul PJ, Åkesson L, Wiking M, Mahdessian
D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM,
et al: A subcellular map of the human proteome. Science.
356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang M, Liu T, Xia B, Yang C, Hou S, Xie
W and Lou G: Platelet-derived growth factor D is a prognostic
biomarker and is associated with platinum resistance in epithelial
ovarian cancer. Int J Gynecol Cancer. 28:323–331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Devailly G, Grandin M, Perriaud L, Mathot
P, Delcros JG, Bidet Y, Morel AP, Bignon JY, Puisieux A, Mehlen P
and Dante R: Dynamics of MBD2 deposition across methylated DNA
regions during malignant transformation of human mammary epithelial
cells. Nucleic Acids Res. 43:5838–5854. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wood KH and Zhou Z: Emerging molecular and
biological functions of MBD2, a reader of DNA methylation. Front
Genet. 7:932016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mahmood N and Rabbani SA: DNA methylation
readers and cancer: Mechanistic and therapeutic applications. Front
Oncol. 9:4892019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Le Guezennec X, Vermeulen M, Brinkman AB,
Hoeijmakers WA, Cohen A, Lasonder E and Stunnenberg HG: MBD2/NuRD
and MBD3/NuRD, two distinct complexes with different biochemical
and functional properties. Mol Cell Biol. 26:843–851. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Magdinier F and Wolffe AP: Selective
association of the methyl-CpG binding protein MBD2 with the silent
p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA.
98:4990–4995. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng L, Tang Y, Chen X, Zhao L, Liu S, Ma
Y, Wang N, Zhou K, Zhou J and Zhou M: Deletion of MBD2 inhibits
proliferation of chronic myeloid leukaemia blast phase cells.
Cancer Biol Ther. 19:676–686. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alvarado S, Wyglinski J, Suderman M,
Andrews SA and Szyf M: Methylated DNA binding domain protein 2
(MBD2) coordinately silences gene expression through activation of
the microRNA hsa-mir-496 promoter in breast cancer cell line. PLoS
One. 8:e740092013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He M, Fan J, Jiang R, Tang WX and Wang ZW:
Expression of DNMTs and MBD2 in GIST. Biomed Rep. 1:223–227. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pei YF, Xu XN, Wang ZF, Wang FW, Wu WD,
Geng JF and Liu XQ: Methyl-CpG binding domain protein 2 inhibits
the malignant characteristic of lung adenocarcinoma through the
epigenetic modulation of 10 to 11 translocation 1 and miR-200s. Am
J Pathol. 189:1065–1076. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berns EM and Bowtell DD: The changing view
of high-grade serous ovarian cancer. Cancer Res. 72:2701–2704.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang RL, Gu F, Kirma NB, Ruan J, Chen CL,
Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, et al: Comprehensive
methylome analysis of ovarian tumors reveals hedgehog signaling
pathway regulators as prognostic DNA methylation biomarkers.
Epigenetics. 8:624–634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu W, Jin C, Lou X, Han X, Li L, He Y,
Zhang H, Ma K, Zhu J, Cheng L and Lin B: Global analysis of DNA
methylation by Methyl-Capture sequencing reveals epigenetic control
of cisplatin resistance in ovarian cancer cell. PLoS One.
6:e294502011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kehoe S, Hook J, Nankivell M, Jayson GC,
Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M,
et al: Primary chemotherapy versus primary surgery for newly
diagnosed advanced ovarian cancer (CHORUS): An open-label,
randomised, controlled, non-inferiority trial. Lancet. 386:249–257.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tsuyoshi H, Orisaka M, Fujita Y,
Asare-Werehene M, Tsang BK and Yoshida Y: Prognostic impact of
dynamin related protein 1 (Drp1) in epithelial ovarian cancer. BMC
Cancer. 20:4672020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ducie J, Dao F, Considine M, Olvera N,
Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L and Levine DA:
Molecular analysis of high-grade serous ovarian carcinoma with and
without associated serous tubal intra-epithelial carcinoma. Nat
Commun. 8:9902017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Joueidi Y, Dion L, Bendifallah S, Mimoun
C, Bricou A, Nyangoh Timoh K, Collinet P, Touboul C, Ouldamer L,
Azaïs H, et al: Management and survival of elderly and very elderly
patients with ovarian cancer: An age-stratified study of 1123 women
from the FRANCOGYN group. J Clin Med. 9:14512020. View Article : Google Scholar
|
|
47
|
Scott LJ: Niraparib: First global
approval. Drugs. 77:1029–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lorusso D, Scambia G, Pignata S, Sorio R,
Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, et
al: Prospective phase II trial of trabectedin in BRCA-mutated
and/or BRCAness phenotype recurrent ovarian cancer patients: The
MITO 15 trial. Ann Oncol. 27:487–493. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fan XM, Zhang J, Niu SH, Li KX and Song
CZ: Secondary cytoreductive surgery in recurrent epithelial ovarian
cancer: A prognostic analysis with 103 cases. Int J Surg. 38:61–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: A
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: By the arbeitsgemeinschaft gynaekologische
onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe
d'Investigateurs nationaux pour les etudes des cancers de l'Ovaire
(GINECO). Cancer. 115:1234–1244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
E C, Li C, Li H and Yang J: Silencing of a
novel lncRNA LOC105369748 suppresses the progression of
hepatocellular carcinoma by sponging miR-5095 from MBD2. J Cell
Physiol. 234:18504–18512. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Campbell PM, Bovenzi V and Szyf M:
Methylated DNA-binding protein 2 antisense inhibitors suppress
tumourigenesis of human cancer cell lines in vitro and in vivo.
Carcinogenesis. 25:499–507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Giovinazzo H, Reichert ZR, Bergman A, Lin
X, Wyhs N, Esopi D, Vaghasia A, Liu J, Jain Y, Bhamidipati A, et
al: Abstract 5881: Novel inhibitors of the epigenetic reader
protein MBD2. Cancer Res. 78 (Suppl 13):S58812018.
|
